# Study of Bioavailability, Pharmacodynamics and Safety of SHR-1209 Administered by Single Subcutaneous Injection at Different Sites in Healthy Volunteers

> **NCT05370950** · PHASE1 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 159 (actual)

## Conditions studied

- Hypercholesterolemia and Hyperlipidemia

## Interventions

- **DRUG:** SHR-1209

## Key facts

- **NCT ID:** NCT05370950
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-25
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 159 (ACTUAL)
- **Last updated:** 2023-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05370950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05370950, "Study of Bioavailability, Pharmacodynamics and Safety of SHR-1209 Administered by Single Subcutaneous Injection at Different Sites in Healthy Volunteers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05370950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*